Facebook
Twitter
LinkedIn
Forward
New Insights on Dry Eye Disease: Targeting Evaporation (Online CME Monograph)
Activity Description and Purpose
Dry eye disease (DED) is a common condition associated with significant quality-of-life and economic burdens. The DED pathogenic pathway is triggered by evaporation and the loss of tear film stability. Pharmacotherapy options for managing DED are expanding with the introduction of a new topical agent targeting evaporation and a novel cyclosporine formulation.
Combining didactic material and case-based discussions presented by an expert faculty, this educational activity reviews DED prevalence, risk factors, pathophysiology, diagnosis, and treatment. The desired results of this activity are to cement ophthalmologists’ knowledge of the role of evaporation in the pathogenesis of DED and help them obtain practical strategies for screening, diagnosis, and effective treatment that can improve patient outcomes.
Target Audience
This educational activity is intended for ophthalmologists.
Learning Objectives
After completing this activity, participants will be better able to:
- Review the function of the tear film in maintaining a healthy ocular surface
- Use diagnostic strategies to identify dry eye disease in routine practice
- Identify treatments for a variety of patients with dry eye disease according to clinical evidence
Faculty
 | Marguerite B. McDonald, MD, FACS (Chair)
|
 | Terry Kim, MD |
 | Cathleen McCabe, MD |
 | William Trattler, MD |
Disclosure Policy
MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.
Faculty
Terry Kim, MD, is a consultant for Alcon, Azura Ophthalmics, Bausch & Lomb Incorporated, Harrow, Inc, Kala Pharmaceuticals, Oyster Point Pharma, Inc, Santen Inc, Surface Pharmaceuticals Inc, Tarsus Pharmaceuticals, Inc, and Thea Pharmaceuticals Limited.
Cathleen McCabe, MD, is a consultant for AbbVie Inc, Alcon, Bausch & Lomb Incorporated, Dompé US, Inc, Easee, EyePoint Pharmaceuticals, Eyevance, Imprimis Pharmaceuticals, Inc, iSTAR Medical, Ivantis Inc, LENSAR, LLC, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Inc, Omeros Corporation, Orasis Pharmaceuticals, Quidel Corporation, ScienceBased Health, Sight Sciences, SpyGlass Ophthalmics, Tarsus Pharmaceuticals, Inc, Visus Therapeutics, and Zeiss; is on the speakers bureau for AbbVie Inc, Alcon, Bausch & Lomb Incorporated, Dompé US, Inc, EyePoint Pharmaceuticals, Ivantis Inc, LENSAR, LLC, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Inc, Omeros Corporation, and Sight Sciences; and is a contracted researcher for Alcon, Glaukos Corporation, Ivantis Inc, Ocular Therapeutix, Inc, Ora, Inc, Orasis Pharmaceuticals, and Sun Pharmaceutical Industries, Inc.
Marguerite B. McDonald, MD, is a consultant for AbbVie Inc, Alcon, Bausch & Lomb Incorporated, Johnson & Johnson Vision Care, Inc, OCULUS, Inc, Ocuphire Pharma, OCuSOFT Inc, Orca Surgical, Oyster Point Pharma, Inc, Sun Pharmaceutical Industries, Inc, and ThermaMEDx, LLC.
William Trattler, MD, is a consultant for AbbVie Inc, Alcon, Azura Ophthalmics, Bausch & Lomb Incorporated, BioTissue, BVI, CSI Dry Eye, Dompé US, Inc, Glaukos Corporation, Horizon Therapeutics plc, Johnson & Johnson Vision Care, Inc, LENSAR, LLC, Ocular Science, OCULUS Surgical, Inc, Sight Sciences, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, Thea Pharmaceuticals Limited, TissueTech, Inc, Trefoil Therapeutics, LLC, Verséa Health, Inc, Visiox Pharmaceuticals, Visus Therapeutics, and Zeiss; is on the speakers bureau for Bausch & Lomb Incorporated, BVI, Sun Pharmaceutical Industries, Inc, and TissueTech, Inc; and has individual stocks or stock options in Aperta Biosciences, LLC, CSI Dry Eye Software, Epion Health, Inc, RxSight, Tarsus Pharmaceuticals, Inc, and Trefoil Therapeutics, LLC.
Peer Reviewer
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners, Managers, and Writers
Medical Writer: Cheryl Guttman has individual stocks or stock options in AbbVie Inc and Johnson & Johnson Vision Care, Inc.
Other MedEdicus planners and managers have no relevant commercial relationships to disclose.
Accreditation Statement
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from Bausch & Lomb Incorporated.
Off-Label Discussion
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or Bausch & Lomb Incorporated.
This CME activity is copyrighted to MedEdicus LLC ©2024. All rights reserved. MedEdicus does not claim copyright to material included herein owned by third parties for which attribution or citation has been made. 311
Available Credit
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Participation